Skip to main content
Fig. 1 | BMC Cardiovascular Disorders

Fig. 1

From: Sacubitril/valsartan inhibits the proliferation of vascular smooth muscle cells through notch signaling and ERK1/2 pathway

Fig. 1

The signaling pathway of sacubitril/valsartan inhibiting VSMCs proliferation. Sacubitril/valsartan can inhibit the migration and proliferation of VSMCs induced by Ang II, which may be through Notch1/Jagged-1 and ERK1/2 pathways. On the one hand, Ang II increases the expression of Notch1 and Jagged-1, causing the proliferation and migration of VSMCs. On the other hand, it activates the ERK1/2 pathway, in which Ras is an upstream activator protein, Raf and MEK1/2 are activated in turn, resulting in increased phosphorylation of ERK1/2. In addition, sacubitril/valsartan also inhibits the decomposition of NPs, thereby inhibiting the proliferation and migration of VSMCs

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us